Step Forward
Personalize treatment decisions for RA patients

PrismRA^® is a first-of-its kind molecular signature test that gives providers objective insights to drive RA treatment decisions.

The blood test analyzes each patient’s unique molecular signature, predicting if a patient is well suited for TNF inhibitor (TNFi) therapies such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab with 90% accuracy.¹

Now, providers can help improve their patients’ outcomes by identifying those unlikely to respond adequately to TNFi therapies prior to treatment initiation and directing them to a more appropriate therapy sooner.